Drugs combination warning following nurse's death
Thirty-four-year old nurse Chloe Burgess died suddenly at her home in September 2024.
Following an inquest into her death, Hampshire coroner Nicholas Walker has issued a Prevention of Future Deaths (PFD) report over the combination of drugs amitriptyline, paroxetine and ivabradine.
He said the risks of the drugs being used together were "not widely appreciated".
The inquest into Ms Burgess' death, held last month, heard she had been prescribed heart medication after a diagnosis of sinus tachycardia - a faster than normal heartbeat.
She had also been prescribed antidepressant medication.
In a report sent to National Institute for Health and Care Excellence (Nice) and the Royal College of Physicians, Mr Walker said the potential danger of the combination of the drugs was "not well-known or appreciated" by those treating her.
She had been using the combination of drugs without concern for four years before she died, the inquest heard.
The coroner returned a narrative conclusion, recording that Ms Burgess died from natural causes contributed to by the effect of medication in combination.
His report said: "It is likely that the medication interacted with each other to raise the levels of amitriptyline in Chloe's blood."
His PFD report said this, combined with an episode of sleep apnoea - where breathing stops and starts during sleep - and her heart medication, had induced "sudden cardiac death".
He said the inquest had heard the combination of amitriptyline, paroxetine and ivabradine does not trigger an alert on the prescribing software used in primary care or by pharmacists.
"In my opinion there is a risk that future deaths could occur unless action is taken," he said.
You can follow BBC Hampshire & Isle of Wight on Facebook, X (Twitter), or Instagram.
HM Coroner's Service
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 days ago
- Medscape
Rare Eye Disease Gets First NHS Drug Recommendation
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending idebenone (Raxone, Chiesi Pharmaceuticals) for treating visual impairment from Leber hereditary optic neuropathy (LHON) in people aged 12 years or older. This is the first time that NICE has recommended a licensed medicine for use on the NHS in England to target the underlying causes of this genetic eye condition. Around 250 individuals in England may be eligible for treatment. Rare Mitochondrial Disorder LHON is a rare mitochondrial genetic disorder caused by a gene mutation that prevents retinal cells from producing enough energy to function normally. This leads to the dysfunction of retinal ganglion cells. The condition typically begins with painless blurring of central vision, which can progress to bilateral blindness within months. It mainly affects boys and young men. Until now, the standard of care was limited to supportive measures such as nutritional supplements, counselling, and lifestyle management, with no licensed medicines available to address the underlying pathophysiology of the disease. How the Drug Works Idebenone is a synthetic short-chain benzoquinone thought to restore the cells' ability to produce energy. This may allow inactive retinal cells to function again and potentially improve vision. NICE's recommendation was based primarily on results from the RHODOS trial, which randomised 85 patients aged 14 or older to receive 900 mg/day of idebenone or placebo for 24 weeks. At 6 months, idebenone produced clinically meaningful improvements in visual acuity, especially in patients with differing vision between eyes at baseline. Visual recovery occurred in 30% of treated patients compared with 10% in the placebo group. Improvements seen as early as one month. A follow-up observational study, RHODOS-OFU, found that improvements were largely maintained, even after idebenone treatment ended. Additional evidence came from the non-randomised long-term EAP, LEROS, and PAROS studies. Safety and Availability Idebenone was generally well tolerated, with adverse events occurring at similar rates to placebo. Reported side effects were typically mild and included headache, nasopharyngitis, and cough. The drug will be available as 150 mg tablets. The recommended dose is two tablets taken three times a day with food. Professor Patrick Yu-Wai-Man, a NICE committee member and professor of ophthalmology at the University of Cambridge, said the recommendation would "come as a great relief to the LHON community". The treatment will be supplied through a confidential commercial arrangement with a patient access scheme that provides a discount to the NHS. NHS England will make the treatment available within 3 months of NICE publishing its final guidance.
Medscape
6 days ago
- Medscape
New NHS Drug Option for Advanced Endometrial Cancer
The National Institute for Health and Care Excellence (NICE) has recommended a combination treatment for advanced endometrial cancer, calling it a 'major step forward'. The final draft guidance allows pembrolizumab (Keytruda, Merck Sharp & Dohme) to be used alongside carboplatin and paclitaxel within its marketing authorisation on the NHS. It applies to adults with previously untreated primary advanced or recurrent endometrial cancer. Treatment should stop after 2 years, or earlier if there is disease progression or unacceptable toxicity, NICE said. First-Line Immunotherapy This is the first time immunotherapy has been combined with chemotherapy as a first-line treatment for this type of cancer. Around 2100 people in England could benefit, the regulator said. The approval overturns NICE's earlier rejection in March, when it found insufficient evidence that the drug combination offered value for money. At the time, it recommended against its use in adults with previously untreated primary, advanced, or recurrent disease. Endometrial cancer is the most common gynaecological cancer in the UK, with almost 10,000 people diagnosed each year. Only 15% of people diagnosed with stage 4 endometrial cancer survive for 5 years or more. People with untreated primary advanced or recurrent endometrial cancer usually have platinum-based chemotherapy, such as the combination carboplatin and paclitaxel. Trial Evidence Showed Reduced Mortality Risk NICE's updated decision was based on evidence from the KEYNOTE-868 study, an ongoing multicentre, randomised, double-blind, phase 3 trial. It is comparing the combination of pembrolizumab with chemotherapy, followed by pembrolizumab maintenance, against chemotherapy alone followed by placebo. NICE said that adding pembrolizumab to chemotherapy reduced the risk of death by 26% compared with chemotherapy alone. Trial data also suggest the treatment slows disease progression, although the effect on overall survival remains uncertain as the trial continues. 'Powerful' New Treatment Option Pembrolizumab is a monoclonal antibody that acts as an immune checkpoint inhibitor. It is administered intravenously and blocks the PD-1 protein on the surface of T cells, allowing them to identify and attack cancer cells. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at NICE. 'It marks a major step forward,' she added. The treatment will be available immediately through England's Cancer Drugs Fund, following a commercial deal that provides the NHS with a discount. Helen Hyndman, the Eve Appeal's Ask Eve lead nurse, told Medscape News UK that NICE's recommendation was 'great news' and would 'offer hope, a better quality of life, and improve outcomes for those affected'.
Yahoo
7 days ago
- Yahoo
Treatment for advanced womb cancer ‘major step forward'
Women with advanced form womb cancer have been given fresh hope after a new treatment was given the green light for widespread NHS use. Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'
